Sonia Viganò

Sonia Viganò

Auto-generated profile, based on publicly available information

Sonia Viganò

Department of Experimental Oncology at IEO, European Institute of Oncology IRCCS, Milan, Italy

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 June 2021 in EMBO Reports
Verified
Journal Article
Open access
PDF file
RWRuoxi W Wang
Ruoxi W Wang
SVSonia Viganò
Sonia Viganò
UBUri Ben-David
Uri Ben-David
AAAngelika Amon
Angelika Amon
SSStefano Santaguida
Stefano Santaguida
The immune system plays a major role in the protection against cancer. Identifying and characterizing the pathways mediating this immune surveillance are thus critical for understanding how cancer cells are recognized and eliminated. Aneuploidy is a hallmark of cancer, and we previously found that untransformed cells that had undergone senescence due to highly abnormal karyotypes are eliminated by natural killer (NK) cells in vitro . However, the mechanisms underlying this process remained elusive. Here, using an in vitro NK cell killing system, we show that non-cell-autonomous mechanisms in aneuploid cells predominantly mediate their clearance by NK cells. Our data indicate that in untransformed aneuploid cells, NF-κB signaling upregulation is central to elicit this immune response. Inactivating NF-κB abolishes NK cell-mediated clearance of untransformed aneuploid cells. In cancer cell lines, NF-κB upregulation also correlates with the degree of aneuploidy. However, such upregulation in cancer cells is not sufficient to trigger NK cell-mediated clearance, suggesting that additional mechanisms might be at play during cancer evolution to counteract NF-κB-mediated immunogenicity.

9 September 2024 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
MIMarica Rosaria. Ippolito
Marica Rosaria. Ippolito
JZJohanna Zerbib
Johanna Zerbib
YEYonatan Eliezer
Yonatan Eliezer
EREli Reuveni
Eli Reuveni
SVSonia Viganò
Sonia Viganò
UBUri Ben-David
Uri Ben-David
Aneuploidy results in a stoichiometric imbalance of protein complexes that jeopardizes cellular fitness. Aneuploid cells thus need to compensate for the imbalanced DNA levels by regulating their RNA and protein levels, but the underlying molecular mechanisms remain unknown. In this study, we dissected multiple diploid versus aneuploid cell models. We found that aneuploid cells cope with transcriptional burden by increasing several RNA degradation pathways, and are consequently more sensitive to the perturbation of RNA degradation. At the protein level, aneuploid cells mitigate proteotoxic stress by reducing protein translation and increasing protein degradation, rendering them more sensitive to proteasome inhibition. These findings were recapitulated across hundreds of human cancer cell lines and primary tumors, and aneuploidy levels were significantly associated with the response of patients with multiple myeloma to proteasome inhibitors. Aneuploid cells are therefore preferentially dependent on several key nodes along the gene expression process, creating clinically actionable vulnerabilities in aneuploid cells. Significance: Aneuploidy is a hallmark of cancer that is associated with poor prognosis and worse drug response. We reveal that cells with extra chromosomes compensate for their imbalanced DNA content by altering their RNA and protein metabolism, rendering them more sensitive to perturbation of RNA and protein degradation. See related commentary by Bakhoum, p. 2315

9 September 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
JZJohanna Zerbib
Johanna Zerbib
MIMarica Rosaria Ippolito
Marica Rosaria Ippolito
YEYonatan Eliezer
Yonatan Eliezer
GFGiuseppina De Feudis
Giuseppina De Feudis
EREli Reuveni
Eli Reuveni
SSStefano Santaguida
Stefano Santaguida
Aneuploidy is a hallmark of human cancer, yet the molecular mechanisms to cope with aneuploidy-induced cellular stresses remain largely unknown. Here, we induce chromosome mis-segregation in non-transformed RPE1-hTERT cells and derive multiple stable clones with various degrees of aneuploidy. We perform a systematic genomic, transcriptomic and proteomic profiling of 6 isogenic clones, using whole-exome DNA, mRNA and miRNA sequencing, as well as proteomics. Concomitantly, we functionally interrogate their cellular vulnerabilities, using genome-wide CRISPR/Cas9 and large-scale drug screens. Aneuploid clones activate the DNA damage response and are more resistant to further DNA damage induction. Aneuploid cells also exhibit elevated RAF/MEK/ERK pathway activity and are more sensitive to clinically-relevant drugs targeting this pathway, and in particular to CRAF inhibition. Importantly, CRAF and MEK inhibition sensitize aneuploid cells to DNA damage-inducing chemotherapies and to PARP inhibitors. We validate these results in human cancer cell lines. Moreover, resistance of cancer patients to olaparib is associated with high levels of RAF/MEK/ERK signaling, specifically in highly-aneuploid tumors. Overall, our study provides a comprehensive resource for genetically-matched karyotypically-stable cells of various aneuploidy states, and reveals a therapeutically-relevant cellular dependency of aneuploid cells.

17 June 2026
Verified
Other
Open access
MIMarica Rosaria Ippolito
Marica Rosaria Ippolito
JZJohanna Zerbib
Johanna Zerbib
YEYonatan Eliezer
Yonatan Eliezer
EREli Reuveni
Eli Reuveni
SVSonia Viganò
Sonia Viganò
UBUri Ben-David
Uri Ben-David
Pre-ranked gene set enrichment analysis of differential mRNA expression between the highly-aneuploid clones (SS51, SS111) and the pseudo-diploid clone (SS48).

17 June 2026
Verified
Other
Open access
MIMarica Rosaria Ippolito
Marica Rosaria Ippolito
JZJohanna Zerbib
Johanna Zerbib
YEYonatan Eliezer
Yonatan Eliezer
EREli Reuveni
Eli Reuveni
SVSonia Viganò
Sonia Viganò
UBUri Ben-David
Uri Ben-David
Details of cell lines, reagents and oligonucleotides used in the study

2 December 2024
Verified
Other
Open access
MIMarica Rosaria Ippolito
Marica Rosaria Ippolito
JZJohanna Zerbib
Johanna Zerbib
YEYonatan Eliezer
Yonatan Eliezer
EREli Reuveni
Eli Reuveni
SVSonia Viganò
Sonia Viganò
UBUri Ben-David
Uri Ben-David
Gene set enrichment analysis of differential protein expression between the highly-aneuploid clones (SS51, SS111) and pseudo-diploid clones (SS48, SS31)